drugset
drugset / Trial / NCT07016750

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

NCT07016750 ↗

Phase 3 Recruiting 16 enrolled Krystal Biotech, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).

Timeline

Start
2025-06-20
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject KB803 Unknown — Other

Indications

generalized dominant dystrophic epidermolysis bullosa recessive dystrophic epidermolysis bullosa